IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Log in (now much improved!)

Citations for "The price of innovation: new estimates of drug development costs"

by DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G.

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window

  1. John Vernon & Joseph Golec & J. Stevens, 2010. "Comparative Effectiveness Regulations and Pharmaceutical Innovation," PharmacoEconomics, Springer, vol. 28(10), pages 877-887, October.
  2. Grillitsch, Markus & Schubert, Torben & Srholec, Martin, 2016. "Knowledge diversity and firm growth: Searching for a missing link," Papers in Innovation Studies 2016/13, Lund University, CIRCLE - Center for Innovation, Research and Competences in the Learning Economy.
  3. Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015. "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
  4. Jing-Yuan Chio & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2012. "The Value of Failures in Pharmaceutical R&D," Working Papers 1/2012, IMT Institute for Advanced Studies Lucca, revised Jan 2012.
  5. Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2011. "Spatial collocation and venture capital in the US biotechnology industry," Research Policy, Elsevier, vol. 40(9), pages 1188-1199.
  6. Engwall, Mats & Freilich, Jonatan, 2014. "Architectural Lock-in of the Drug Development Process," INDEK Working Paper Series 2014/4, Department of Industrial Economics and Management, Royal Institute of Technology.
  7. Vernon, John A. & Golec, Joseph H. & Lutter, Randall & Nardinelli, Clark, 2009. "An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending," The Quarterly Review of Economics and Finance, Elsevier, vol. 49(4), pages 1260-1274, November.
  8. Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
  9. Patzelt, Holger & zu Knyphausen-Aufseß, Dodo & Fischer, Heiko T., 2009. "Upper echelons and portfolio strategies of venture capital firms," Journal of Business Venturing, Elsevier, vol. 24(6), pages 558-572, November.
  10. Michele Boldrin & David K Levine, 2012. "The Case Against Patents," Levine's Working Paper Archive 786969000000000465, David K. Levine.
  11. Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
  12. Lang, Hui-Chu & Scheffler, Richard M. & Hu, Teh-wei, 2010. "The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--A global pharmaceutical data analysis," Health Policy, Elsevier, vol. 97(1), pages 71-78, September.
  13. Divya Srivastava & Alistair McGuire, 2013. "Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?," LSE Research Online Documents on Economics 54487, London School of Economics and Political Science, LSE Library.
  14. Mueller-Langer, Frank, 2011. "Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting research?," MPRA Paper 40193, University Library of Munich, Germany.
  15. Rose.Janna L. & Quave, Cassandra L. & Islam, Gazi, 2011. "The Four-Sided Triangle of Ethics in Bioprospecting: Pharmaceutical Business, International Politics, Socio-Environmental Responsibility and the Importance of Local Stakeholders," Insper Working Papers wpe_267, Insper Working Paper, Insper Instituto de Ensino e Pesquisa.
  16. Tannista Banerjee & Stephen Martin, 2013. "Pharmaceutical regulation and innovative performance: a decision-theoretic model," Auburn Economics Working Paper Series auwp2013-21, Department of Economics, Auburn University.
  17. Jommi, Claudio & Paruzzolo, Silvia, 2007. "Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study," Health Policy, Elsevier, vol. 81(1), pages 117-130, April.
  18. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
  19. Patricia M. Danzon & Andrew J. Epstein, 2008. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," NBER Working Papers 14041, National Bureau of Economic Research, Inc.
  20. Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009. "An Economic Evaluation of the War on Cancer," NBER Working Papers 15574, National Bureau of Economic Research, Inc.
  21. Stefano Capri & Rosella Levaggi, 2005. "Reconciling social and industrial goals: a bargaining model to pricing pharmaceuticals," LIUC Papers in Economics 170, Cattaneo University (LIUC).
  22. Ghauri, Pervez N. & Rao, P.M., 2009. "Intellectual property, pharmaceutical MNEs and the developing world," Journal of World Business, Elsevier, vol. 44(2), pages 206-215, April.
  23. Newhouse, Joseph Paul & Berndt, Ernst R., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles 4450127, Harvard Kennedy School of Government.
  24. Raphael Greiner & Siah Ang, 2012. "Biotechnology collaborations: does business model matter?," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 16(3), pages 377-392, August.
  25. Giulia Trombini & Anna Comacchio, 2012. "Cooperative Markets for Ideas: When does Technology Licensing Combine with R&D Partnerships?," Working Papers 8, Department of Management, Università Ca' Foscari Venezia.
  26. Charles R. Hulten & Xiaohui Hao, 2008. "What is a Company Really Worth? Intangible Capital and the "Market to Book Value" Puzzle," NBER Working Papers 14548, National Bureau of Economic Research, Inc.
  27. Hirai, Yuka & Yamanaka, Yosuke & Kusama, Makiko & Ishibashi, Taro & Sugiyama, Yuichi & Ono, Shunsuke, 2012. "Analysis of the success rates of new drug development in Japan and the lag behind the US," Health Policy, Elsevier, vol. 104(3), pages 241-246.
  28. Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
  29. Malueg, David A. & Snyder, Christopher M., 2006. "Bounding the relative profitability of price discrimination," International Journal of Industrial Organization, Elsevier, vol. 24(5), pages 995-1011, September.
  30. Patricia M. Danzon & Sean Nicholson & Nuno Sousa Pereira, 2003. "Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances," NBER Working Papers 9615, National Bureau of Economic Research, Inc.
  31. Mathias Kifmann & Sven Neelsen, 2010. "Germany's Struggle with Prices for Patent-protected Drugs," CESifo DICE Report, Ifo Institute - Leibniz Institute for Economic Research at the University of Munich, vol. 8(3), pages 43-52, October.
  32. Filson, Darren & Oweis, Ahmed, 2010. "The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(4), pages 575-584, July.
  33. Ming Liu & Sumner La Croix, 2014. "A Cross-Country Index of Intellectual Property Rights in Pharmaceutical Innovations," Working Papers 2014-13, University of Hawaii Economic Research Organization, University of Hawaii at Manoa.
  34. Thomas A. Abbott & John A. Vernon, 2005. "The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions," NBER Working Papers 11114, National Bureau of Economic Research, Inc.
  35. Frank Windmeijer & Eric de Laat & Rudy Douven & Esther Mot, 2006. "Pharmaceutical promotion and GP prescription behaviour," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 5-18.
  36. Papachristos, George & Adamides, Emmanuel, 2016. "A retroductive systems-based methodology for socio-technical transitions research," Technological Forecasting and Social Change, Elsevier, vol. 108(C), pages 1-14.
  37. Entorf, Horst & Fegert, Jörg & Kölch, Michael, 2004. "Children in Need of Medical Innovation," ZEW Discussion Papers 04-49, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
  38. Mudambi, Ram & Swift, Tim, 2011. "Proactive R&D management and firm growth: A punctuated equilibrium model," Research Policy, Elsevier, vol. 40(3), pages 429-440, April.
  39. Lorenz, Steffi, 2015. "Diversität und Verbundenheit der unternehmerischen Wissensbasis: Ein neuartiger Messansatz mit Indikatoren aus Innovationsprojekten," Discussion Papers on Strategy and Innovation 15-01, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
  40. Giaccotto, Carmelo & Golec, Joseph & Vernon, John, 2011. "New estimates of the cost of capital for pharmaceutical firms," Journal of Corporate Finance, Elsevier, vol. 17(3), pages 526-540, June.
  41. Magazzini Laura & Fabio Pammolli, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT Institute for Advanced Studies Lucca, revised Jul 2013.
  42. Darius Lakdawalla & Neeraj Sood, 2007. "The Welfare Effects of Public Drug Insurance," NBER Working Papers 13501, National Bureau of Economic Research, Inc.
  43. John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16.
  44. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Starving (or Fattening) the Golden Goose?: Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
  45. Costello, Christopher & Ward, Michael, 2006. "Search, bioprospecting and biodiversity conservation," Journal of Environmental Economics and Management, Elsevier, vol. 52(3), pages 615-626, November.
  46. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(02), pages 185-208, April.
  47. Jacoline Bouvy & Just Weemers & Huub Schellekens & Marc Koopmanschap, 2011. "Willingness to Pay for Adverse Drug Event Regulatory Actions," PharmacoEconomics, Springer, vol. 29(11), pages 963-975, November.
  48. Ernst Berndt & Iain Cockburn & Karen Grépin, 2006. "The Impact of Incremental Innovation in Biopharmaceuticals," PharmacoEconomics, Springer, vol. 24(2), pages 69-86, December.
  49. Pedro Pita Barros & Xavier Martínez-Giralt, 2006. "On insurance and the cost-sharing of pharmaceutical R&D," Working Papers 293, Barcelona Graduate School of Economics.
  50. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo Group Munich.
  51. Dean Baker, 2007. "Stagnation in the Drug Development Process: Are Patents the Problem?," CEPR Reports and Issue Briefs 2007-07, Center for Economic and Policy Research (CEPR).
  52. Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008. "Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts," Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
  53. Arora, Ashish & Gambardella, Alfonso & Magazzini, Laura & Pammolli, Fabio, 2007. "A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development," MPRA Paper 16042, University Library of Munich, Germany.
  54. Tannista Banerjee & Ralph Siebert, 2013. "The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry," Auburn Economics Working Paper Series auwp2013-20, Department of Economics, Auburn University.
  55. Ilan Guedj & David Scharfstein, 2004. "Organizational Scope and Investment: Evidence from the Drug Development Strategies and Performance of Biopharmaceutical Firms," NBER Working Papers 10933, National Bureau of Economic Research, Inc.
  56. Waters, James, 2014. "Introduction of innovations during the 2007-8 financial crisis: US companies compared with universities," MPRA Paper 59016, University Library of Munich, Germany.
  57. Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
  58. Sean M. Dougherty & Robert Inklaar & Robert H. McGuckin & Bart van Ark, 2007. "International Comparisons of R&D Expenditure: Does an R&D PPP Make a Difference?," NBER Working Papers 12829, National Bureau of Economic Research, Inc.
  59. Häussler, Carolin, 2006. "Can’t Buy Me Rights! The Contractual Structure of Asymmetrical Inter-firm Collaborations," Discussion Paper Series of SFB/TR 15 Governance and the Efficiency of Economic Systems 189, Free University of Berlin, Humboldt University of Berlin, University of Bonn, University of Mannheim, University of Munich.
  60. Mark Duggan & Fiona Scott Morton, 2008. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," NBER Working Papers 13917, National Bureau of Economic Research, Inc.
  61. Christopher J. Longo, 2011. "Encouraging pharmaceutical innovation to meet the needs of both developed and developing countries," International Journal of Development Issues, Emerald Group Publishing, vol. 10(1), pages 92-101, June.
  62. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," NBER Working Papers 16990, National Bureau of Economic Research, Inc.
  63. Winghan Kwong & Edward Norton, 2007. "The Effect of Advertising on Pharmaceutical Innovation," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(3), pages 221-236, November.
  64. Stefan Wagner & Simon Wakeman, 2014. "What do patent-based measures tell us about product commercialization? Evidence from the pharmaceutical industry," ESMT Research Working Papers ESMT-14-01 (R1), ESMT European School of Management and Technology, revised 09 Mar 2015.
  65. Sorisio, Enrico & Strøm, Steinar, 2009. "Innovation and market dynamics in the EPO market," HERO On line Working Paper Series 2006:3, Oslo University, Health Economics Research Programme.
  66. Pedro Barros & Xavier Martinez-Giralt, 2008. "On international cost-sharing of pharmaceutical R&D," International Journal of Health Economics and Management, Springer, vol. 8(4), pages 301-312, December.
  67. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
  68. Frank, Richard G., 2003. "New estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 325-330, March.
  69. Fier, Andreas & Heneric, Oliver, 2005. "Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry," ZEW Discussion Papers 05-60, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
  70. Yin, Wesley, 2009. "R&D policy, agency costs and innovation in personalized medicine," Journal of Health Economics, Elsevier, vol. 28(5), pages 950-962, September.
  71. Helga De Doncker, 2006. "R&D in the Belgian Pharmaceutical Sector," Working Paper Document 106, National Bank of Belgium.
  72. Grinols, Earl L. & Lin, Hwan C., 2011. "Patent replacement and welfare gains," Journal of Economic Dynamics and Control, Elsevier, vol. 35(9), pages 1586-1604, September.
  73. C. Scott Hemphill & Bhaven N. Sampat, 2012. "Weak Patents Are a Weak Deterrent: Patent Portfolios, the Orange Book Listing Standard, and Generic Entry in Pharmaceuticals," NBER Chapters, in: Standards, Patents and Innovations National Bureau of Economic Research, Inc.
  74. Philip Sauré, 2015. "The Resilient Trade Surplus, the Pharmaceutical Sector, and Exchange Rate Assessments in Switzerland," Working Paper Series WP15-11, Peterson Institute for International Economics.
  75. Marcela Miozzo & Lori DiVito & Panos Desyllas, 2011. "Cross-border acquisitions of science-based firms: Their effect on innovation in the acquired firm and the local science," DRUID Working Papers 11-17, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
  76. Andreas Sturm & Michael J. Dowling & Klaus Röder, 2007. "FDA Drug Approvals: Time Is Money!," Journal of Entrepreneurial Finance, Pepperdine University, Graziadio School of Business and Management, vol. 12(2), pages 23-54, Fall.
  77. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2009. "Nuove politiche per l'innovazione nel settore delle scienze della vita," Working Papers 03-2009, Competitività Regole Mecati (CERM).
  78. Mikuláš Luptáčik & Wolfgang Koller & Bernhard Mahlberg & Herwig W. Schneider, 2008. "Growth and Employment Potentials of Chosen Technology Fields," Czech Economic Review, Charles University Prague, Faculty of Social Sciences, Institute of Economic Studies, vol. 2(1), pages 041-075, March.
  79. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.
  80. Kunter Gunasti & Hans Baumgartner, 2016. "The Asymmetric Effects of Positive Or Negative Experiences with an Extension on Low- or High-Equity Parent Brands: A Microtheoretical Notion," Customer Needs and Solutions, Springer;Institute for Sustainable Innovation and Growth (iSIG), vol. 3(3), pages 126-143, December.
  81. Wagstaff, Adam & Culyer, Anthony J., 2012. "Four decades of health economics through a bibliometric lens," Journal of Health Economics, Elsevier, vol. 31(2), pages 406-439.
  82. Mc Namara, Peter & Baden-Fuller, Charles, 2007. "Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms," Research Policy, Elsevier, vol. 36(4), pages 548-565, May.
  83. Ernst R. Berndt & Adrian H. B. Gottschalk & Matthew W. Strobeck, 2006. "Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the FDA," NBER Chapters, in: Innovation Policy and the Economy, Volume 6, pages 91-122 National Bureau of Economic Research, Inc.
  84. Ng, Desmond W., 2011. "Thinking Outside the Box: An Absorptive Capacity Approach to the Product Development Process," International Food and Agribusiness Management Review, International Food and Agribusiness Management Association (IFAMA), vol. 14(3).
  85. Desmond Sheridan & Jim Attridge, 2006. "The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine," PharmacoEconomics, Springer, vol. 24(2), pages 35-54, December.
  86. Henry Grabowski & John Vernon & Joseph DiMasi, 2003. "Returns on R&D for 1990s New Drug Introductions," Levine's Working Paper Archive 618897000000000666, David K. Levine.
  87. Kelton, Christina M.L. & Rebelein, Robert P., 2005. "A General-Equilibrium Analysis of Public Policy for Pharmaceutical Prices," Vassar College Department of Economics Working Paper Series 78, Vassar College Department of Economics.
  88. Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
  89. Fleischhacker, Adam J. & Zhao, Yao, 2011. "Planning for demand failure: A dynamic lot size model for clinical trial supply chains," European Journal of Operational Research, Elsevier, vol. 211(3), pages 496-506, June.
  90. Hermans, Raine & Kulvik, Martti, 2005. "Initiatives on a Sustainable Development Strategy for Finnish Biotechnology," Discussion Papers 988, The Research Institute of the Finnish Economy.
  91. Bardey, David & Bommier, Antoine & Jullien, Bruno, 2009. "Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 09-026, Toulouse School of Economics (TSE).
  92. Simona Gamba, 2016. "The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector," CESifo Working Paper Series 6004, CESifo Group Munich.
  93. Oliver Baumann & Hariolf Grupp, 2008. "Firm boundary decisions: the market for health-related R&D services with an empirical case study for Germany," International Economics and Economic Policy, Springer, vol. 5(3), pages 297-321, November.
  94. Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
  95. Bérard, Céline & Perez, Marie, 2014. "Alliance dynamics through real options: The case of an alliance between competing pharmaceutical companies," European Management Journal, Elsevier, vol. 32(2), pages 337-349.
  96. Abdulkadir Civan, 2009. "An Alternative Patent Mechanism for Pharmaceutical Drugs for Tropical Diseases," European Journal of Economic and Political Studies, Fatih University, vol. 2(1), pages 21-38.
  97. Dean Baker, 2008. "The Benefits and Savings of Publicly-Funded Clinical Trials of Prescription Drugs," CEPR Reports and Issue Briefs 2008-09, Center for Economic and Policy Research (CEPR).
  98. Colvin, Matthew & Maravelias, Christos T., 2010. "Modeling methods and a branch and cut algorithm for pharmaceutical clinical trial planning using stochastic programming," European Journal of Operational Research, Elsevier, vol. 203(1), pages 205-215, May.
  99. Shichun Xu & Erin Cavusgil & Seyda Deligonul, 2016. "Number Of R&D Alliances And Innovation Output — Nonlinear Relationship Evidence From The Pharmaceutical Industry," International Journal of Innovation Management (ijim), World Scientific Publishing Co. Pte. Ltd., vol. 20(06), pages 1650060-01 .
  100. Gleason, Katherine I. & Klock, Mark, 2006. "Intangible capital in the pharmaceutical and chemical industry," The Quarterly Review of Economics and Finance, Elsevier, vol. 46(2), pages 300-314, May.
  101. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
  102. Trusheim Mark R. & Aitken Murray L. & Berndt Ernst R., 2010. "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?," Forum for Health Economics & Policy, De Gruyter, vol. 13(1), pages 1-45, July.
  103. Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
  104. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
  105. Carolin Häussler & Hans-Martin Zademach, 2007. "Cluster Performance Reconsidered: Structure, Linkages and Paths in the German Bioteehnology Industry, 1996-2003," Schmalenbach Business Review (sbr), LMU Munich School of Management, vol. 59(3), pages 261-281, July.
  106. Darren Filson & Neal Masia, 2007. "Effects of profit-reducing policies on firm survival, financial performance, and new drug introductions in the research-based pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 329-351.
  107. Tomas J. Philipson & Eric Sun, 2008. "Is the Food And Drug Administration Safe And Effective?," Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
  108. Nishimura, Junichi & Okada, Yosuke, 2014. "R&D portfolios and pharmaceutical licensing," Research Policy, Elsevier, vol. 43(7), pages 1250-1263.
  109. William S. Comanor & Stuart O. Schweitzer, 2007. "Determinants of drug prices and expenditures," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 357-370.
  110. Corinne Sauer & Robert Sauer, 2007. "Is it possible to have cheaper drugs and preserve the incentive to innovate? The benefits of privatizing the drug approval process," The Journal of Technology Transfer, Springer, vol. 32(5), pages 509-524, October.
  111. Grönqvist, Erik & Lundin, Douglas, 2006. "Incentives for Clinical Trials," SSE/EFI Working Paper Series in Economics and Finance 636, Stockholm School of Economics.
  112. Fisher, Jill A. & Cottingham, Marci D. & Kalbaugh, Corey A., 2015. "Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities," Social Science & Medicine, Elsevier, vol. 131(C), pages 322-330.
  113. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni, 2008. "Patent Value and R&D Competition," Working Papers 51/2008, University of Verona, Department of Economics.
  114. Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
  115. Thomas A. Abbott & John A. Vernon, 2007. "The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 293-306.
  116. Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
  117. Stephane Régnier, 2013. "What is the value of ‘me-too’ drugs?," Health Care Management Science, Springer, vol. 16(4), pages 300-313, December.
  118. Joseph Golec & John Vernon, 2009. "Financial risk of the Biotech Industry versus the Pharmaceutical Industry," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 155-165, September.
  119. Christian Schröder, 2009. "Financial System and Innovations: Determinants of Early Stage Venture Capital in Europe," EIIW Discussion paper disbei167, Universitätsbibliothek Wuppertal, University Library.
  120. Dean Baker, 2006. "The Conservative Nanny State," CEPR Books, Center for Economic and Policy Research (CEPR), number 2006-01, June.
  121. Angel Leon & Diego Piñeiro, 2004. "Valuation Of A Biotech Company: A Real Options Approach," Working Papers wp2004_0420, CEMFI.
  122. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680, June.
  123. Joseph Golec & John Vernon, 2010. "Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms," PharmacoEconomics, Springer, vol. 28(8), pages 615-628, August.
  124. Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
  125. Pammolli, Fabio & Riccaboni, Massimo, 2004. "Market Structure and Drug Innovation," MPRA Paper 16212, University Library of Munich, Germany.
  126. Henry Grabowski & Y. Richard Wang, 2008. "Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," Journal of Law and Economics, University of Chicago Press, vol. 51(2), pages 377-406, 05.
  127. König, Michael D. & Battiston, Stefano & Napoletano, Mauro & Schweitzer, Frank, 2012. "The efficiency and stability of R&D networks," Games and Economic Behavior, Elsevier, vol. 75(2), pages 694-713.
  128. Chellaraj, Gnanaraj & Maskus, Keith E. & Mattoo, Aaditya, 2005. "The contribution of skilled immigration and international graduate students to U.S. innovation," Policy Research Working Paper Series 3588, The World Bank.
  129. Joseph Cook & Graeme Hunter & John Vernon, 2009. "The Future Costs, Risks and Rewards of Drug Development," PharmacoEconomics, Springer, vol. 27(5), pages 355-363, May.
  130. Erin Cavusgil, 2007. "Merck and Vioxx: An Examination of an Ethical Decision-Making Model," Journal of Business Ethics, Springer, vol. 76(4), pages 451-461, December.
  131. Rutger P. Daems PhD & Edith L. Maes DBA, 2013. "Pharmaceutical Portfolio Management: Global Disease Burden and Corporate Performance Metrics," Working Papers 2013/07, Maastricht School of Management.
  132. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, Elsevier.
  133. Mark Trusheim & Murray L. Aitken & Ernst R. Berndt, 2010. "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?," NBER Working Papers 16014, National Bureau of Economic Research, Inc.
  134. Garcia-Goni, Manuel & Maroto, Andres & Rubalcaba, Luis, 2007. "Innovation and motivation in public health professionals," Health Policy, Elsevier, vol. 84(2-3), pages 344-358, December.
  135. John A. Vernon & W. Keener Hughen, 2005. "The Future of Drug Development: The Economics of Pharmacogenomics," NBER Working Papers 11875, National Bureau of Economic Research, Inc.
  136. Colvin, Matthew & Maravelias, Christos T., 2011. "R&D pipeline management: Task interdependencies and risk management," European Journal of Operational Research, Elsevier, vol. 215(3), pages 616-628, December.
  137. Haeussler, Carolin & Patzelt, Holger & Zahra, Shaker A., 2012. "Strategic alliances and product development in high technology new firms: The moderating effect of technological capabilities," Journal of Business Venturing, Elsevier, vol. 27(2), pages 217-233.
  138. Comanor, William S. & Scherer, F.M., 2013. "Mergers and innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 32(1), pages 106-113.
  139. Michael R. Darby & Lynne G. Zucker, 2006. "Innovation, Competition and Welfare-Enhancing Monopoly," NBER Working Papers 12094, National Bureau of Economic Research, Inc.
  140. Xiaoqing Li & Yu Zheng & Catherine L. Wang, 2016. "Inter-firm collaboration in new product development in Chinese pharmaceutical companies," Asia Pacific Journal of Management, Springer, vol. 33(1), pages 165-193, March.
  141. Joseph A. DiMasi & Henry G. Grabowski, 2007. "The cost of biopharmaceutical R&D: is biotech different?," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 469-479.
  142. Garavaglia Christian & Malerba Franco & Orsenigo Luigi & Pezzoni Michele, 2014. "Innovation and Market Structure in Pharmaceuticals: An Econometric Analysis on Simulated Data," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 234(2-3), pages 274-298, April.
  143. Katherine Sauer, 2008. "A model of parallel imports of pharmaceuticals with endogenous price controls," Economics Bulletin, AccessEcon, vol. 6(36), pages 1-8.
  144. Yaroslav Kryukov, . "Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry," GSIA Working Papers 2015-E33, Carnegie Mellon University, Tepper School of Business.
  145. John A. Vernon & W. Keener Hughen, 2006. "The Future of Drug Development: the Economics of Pharmacogenomics," Working Papers id:589, eSocialSciences.
  146. Michael Buckley, 2013. "A Constructivist Approach to Business Ethics," Journal of Business Ethics, Springer, vol. 117(4), pages 695-706, November.
  147. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.
  148. Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
  149. Natalie Chun & Minjung Park, 2013. "The impact of health insurance mandates on drug innovation: evidence from the United States," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 323-344, April.
  150. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
  151. Matthias Dahm & Paula González & Nicolás Porteiro, 2008. "Trials, Tricks and Transparency: How Disclosure Rules Affect Clinical Knowledge," Working Papers 08.02, Universidad Pablo de Olavide, Department of Economics.
  152. Adrian Towse, 2007. "If it ain't broke, don't price fix it: the OFT and the PPRS," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 653-665.
  153. Christian Zeller & Andreas Hametner & Koen Smet & Markus Seiwald, 2014. "Internationale Expansion in der pharmazeutischen Industrie Österreichs," FIW Research Reports series V-004, FIW.
  154. Stephen Dunn, 2006. "Prolegomena to a Post Keynesian health economics," Review of Social Economy, Taylor & Francis Journals, vol. 64(3), pages 273-299.
  155. Clara I. Gonzalez & Ricardo Gimeno, 2008. "Financial Analysts impact on Stock Volatility. A Study on the Pharmaceutical Sector," Working Papers 2008-19, FEDEA.
  156. repec:ebl:ecbull:v:6:y:2008:i:36:p:1-8 is not listed on IDEAS
  157. Christian Garavaglia & Michele Pezzoni & Luigi Orsenigo & Franco Malerba, 2012. "Technological regimes and demand structure in the evolution of the pharmaceutical industry," Post-Print halshs-01074513, HAL.
  158. Panattoni, Laura E., 2011. "The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms," Journal of Health Economics, Elsevier, vol. 30(1), pages 126-145, January.
  159. Philipson Tomas J. & Sun Eric & Goldman Dana & Jena Anupam B., 2012. "A Reexamination of the Costs of Medical R&D Regulation," Forum for Health Economics & Policy, De Gruyter, vol. 15(2), pages 1-28, October.
  160. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
  161. Königbauer, Ingrid, 2006. "Dealing with Rising Health Care Costs: The Case of Pharmaceuticals," Munich Dissertations in Economics 5640, University of Munich, Department of Economics.
  162. Farre-Mensa, Joan & Hegde, Deepak & Ljungqvist, Alexander P., 2016. "The Bright Side of Patents," CEPR Discussion Papers 11091, C.E.P.R. Discussion Papers.
  163. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
  164. Dean Baker, 2016. "Publicly Funded Clinical Trials: A Route to Sustained Innovation with Affordable Drugs," CEPR Reports and Issue Briefs 2016-02, Center for Economic and Policy Research (CEPR).
  165. Marcello Basili & Roberto Renò & Carlo Zappia, 2005. "Production of a New Drug: A Sequential Investment ProcessUnder Uncertainty," Department of Economics University of Siena 453, Department of Economics, University of Siena.
  166. Henry G. Grabowski & Margaret Kyle, 2007. "Generic competition and market exclusivity periods in pharmaceuticals," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 491-502.
  167. Joseph P. Cook & Graeme Hunter & John A. Vernon, 2010. "Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures," NBER Working Papers 15723, National Bureau of Economic Research, Inc.
  168. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.
  169. Christopher Paul Adams & Van Vu Brantner, 2010. "Spending on new drug development," Health Economics, John Wiley & Sons, Ltd., vol. 19(2), pages 130-141.
  170. Lo Nigro, Giovanna & Perrone, Giovanni & Chiapparrone, Silvia, 2012. "Governance forms drivers in bio-pharmaceutical inter-firm relationships," International Journal of Production Economics, Elsevier, vol. 140(2), pages 604-613.
  171. König, Michael D. & Battiston, S. & Napoletano, M. & Schweitzer, F., 2011. "Recombinant knowledge and the evolution of innovation networks," Journal of Economic Behavior & Organization, Elsevier, vol. 79(3), pages 145-164, August.
  172. Pronker, Esther & Weenen, Tamar & Commandeur, Harry & Claassen, E. & Osterhaus, A.D.M.E., 2015. "Scratching the surface: Exploratory analysis of key opinion leaders on rate limiting factors in novel adjuvanted-vaccine development," Technological Forecasting and Social Change, Elsevier, vol. 90(PB), pages 420-432.
  173. Bradley T. Shapiro, 2016. "Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR," Quantitative Marketing and Economics (QME), Springer, vol. 14(3), pages 201-231, September.
  174. Hermans, Raine & Kamien, Morton & Kulvik, Martti & Löffler, Alicia & Shalowitz, Joel (ed.), . "Medical Innovation and Government Intervention," ETLA B, The Research Institute of the Finnish Economy, number 236.
  175. Edith Maes & Rutger Daems, 2011. "Perspectives on Public Private Partnership: The R&D Based Vaccine Industry," Working Papers 2011/36, Maastricht School of Management.
  176. Lazonick, William & Tulum, Öner, 2011. "US biopharmaceutical finance and the sustainability of the biotech business model," Research Policy, Elsevier, vol. 40(9), pages 1170-1187.
  177. Lo Nigro, Giovanna & Morreale, Azzurra & Enea, Gianluca, 2014. "Open innovation: A real option to restore value to the biopharmaceutical R&D," International Journal of Production Economics, Elsevier, vol. 149(C), pages 183-193.
  178. Joseph H. Golec & John A. Vernon, 2006. "European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending," NBER Working Papers 12676, National Bureau of Economic Research, Inc.
  179. Liu, Ming & La Croix, Sumner, 2015. "A cross-country index of intellectual property rights in pharmaceutical inventions," Research Policy, Elsevier, vol. 44(1), pages 206-216.
  180. Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
  181. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
  182. Drechsler, Wenzel & Natter, Martin, 2012. "Understanding a firm's openness decisions in innovation," Journal of Business Research, Elsevier, vol. 65(3), pages 438-445.
  183. Frank R. Lichtenberg, 2005. "Pharmaceutical Knowledge-Capital Accumulation and Longevity," NBER Chapters, in: Measuring Capital in the New Economy, pages 237-274 National Bureau of Economic Research, Inc.
  184. Atanassov, Atanas & Bahieldin, Ahmed & Brink, Johan & Burachik, Moises & Cohen, Joel I. & Dhawan, Vibha & Ebora, Reynaldo V. & Falck-Zepeda, José & Herrera-Estrella, Luis & Komen, John & Chon Low, Fee, 2004. "To reach the poor: results from the ISNAR-IFPRI Next Harvest study on genetically modified crops, public research, and policy implications," EPTD discussion papers 116, International Food Policy Research Institute (IFPRI).
  185. S. Perez-Vega & E. Ortega-Rivas & I. Salmeron-Ochoa & P. Sharratt, 2013. "A system view of solvent selection in the pharmaceutical industry: towards a sustainable choice," Environment, Development and Sustainability: A Multidisciplinary Approach to the Theory and Practice of Sustainable Development, Springer, vol. 15(1), pages 1-21, February.
This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.